The Inhibition of Vessel Co-Option as an Emerging Strategy for Cancer Therapy
International Journal of Molecular Sciences · 11.01.2024 · 25 (2) · 921
DOI: 10.3390/ijms25020921 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 11.01.2024. Verfasst von Iván Carrera-Aguado und 5 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Bioquímica y Biología Molecular, Universidad de Salamanca, 37007 Salamanca, Spain. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 167 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundación Científica Asociación Española Contra el Cáncer, Instituto de Salud Carlos III, Junta de Castilla y León and European Social Fund.
Abstract (Originalsprache)
Vessel co-option (VCO) is a non-angiogenic mechanism of vascularization that has been associated to anti-angiogenic therapy. In VCO, cancer cells hijack the pre-existing blood vessels and use them to obtain oxygen and nutrients and invade adjacent tissue. Multiple primary tumors and metastases undergo VCO in highly vascularized tissues such as the lungs, liver or brain. VCO has been associated with a worse prognosis. The cellular and molecular mechanisms that undergo VCO are poorly understood. Recent studies have demonstrated that co-opted vessels show a quiescent phenotype in contrast to angiogenic tumor blood vessels. On the other hand, it is believed that during VCO, cancer cells are adhered to basement membrane from pre-existing blood vessels by using integrins, show enhanced motility and a mesenchymal phenotype. Other components of the tumor microenvironment (TME) such as extracellular matrix, immune cells or extracellular vesicles play important roles in vessel co-option maintenance. There are no strategies to inhibit VCO, and thus, to eliminate resistance to anti-angiogenic therapy. This review summarizes all the molecular mechanisms involved in vessel co-option analyzing the possible therapeutic strategies to inhibit this process.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departamento de Bioquímica y Biología Molecular, Universidad de Salamanca, 37007 Salamanca, Spain.
- Instituto de Investigación Biomédica de Salamanca (IBSAL), 37007 Salamanca, Spain.
ORCID-Profile: Iván Carrera-Aguado, Laura Marcos-Zazo, Patricia Carrancio-Salán
Förderung
- Fundación Científica Asociación Española Contra el Cáncer
- Instituto de Salud Carlos III
- Junta de Castilla y León and European Social Fund
- Fundación General de la Universidad de Salamanca
- Fundación Científica de la Asociación Española Contra el Cáncer
- Junta Castilla y León and European Social Fund
Zitieren
APA
Carrera-Aguado, I., Marcos-Zazo, L., Carrancio-Salán, P., Guerra-Paes, E., Sánchez-Juanes, F., & Muñoz-Félix, J. M. (2024). The Inhibition of Vessel Co-Option as an Emerging Strategy for Cancer Therapy. International Journal of Molecular Sciences, 25(2), 921. https://doi.org/10.3390/ijms25020921
Vancouver
Carrera-Aguado I, Marcos-Zazo L, Carrancio-Salán P, Guerra-Paes E, Sánchez-Juanes F, Muñoz-Félix JM. The Inhibition of Vessel Co-Option as an Emerging Strategy for Cancer Therapy. International Journal of Molecular Sciences. 2024;25(2):921. doi:10.3390/ijms25020921
BibTeX
@article{CarreraAguado2024,
author = {Carrera-Aguado, Iván and Marcos-Zazo, Laura and Carrancio-Salán, Patricia and Guerra-Paes, Elena and Sánchez-Juanes, Fernando and Muñoz-Félix, José M},
title = {The Inhibition of Vessel Co-Option as an Emerging Strategy for Cancer Therapy},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {2},
pages = {921},
doi = {10.3390/ijms25020921}
}
EUVIMED